Pfizer (NYSE:PFE) and its partner Arvinas (NASDAQ:ARVN) for the experimental breast cancer drug vepdegestrant announced mixed initial results from a Phase 3 trial for the protein degrader on Tuesday.

Oppenheimer downgraded Arvinas (ARVN) to Perform from Outperform. Effectively assess a stock's risks and opportunities with a clear breakdown of its positive and negative factors. Uncover ...

Arvinas (ARVN) and Pfizer (PFE) announced topline results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor ...

As of March 4 at 9:39:54 AM EST. Market Open.

As of February 18 at 10:57:44 AM EST. Market Open.